Decentralized in Action: How Science 37 Accelerated Enrollment for a Diagnostic Oncology Trial

A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold standard cancer screening procedure.

Download to learn how the Science 37 Direct-to-Patient Site delivered:

• Nearly 50% of the entire study with 24.2% minority representation
• Recruitment and access across 50 states
• 3 year reduction of clinical trial timeline